AbbVie Inc.
Methods of Treating Acute HCV

Abstract:

The present invention features interferon-free therapies for the treatment of acute HCV. Preferably, the treatment is over a shorter duration of treatment, such as 6 weeks. In one aspect, the treatment comprises administering two direct acting antiviral agents to a subject with acute HCV infection, wherein the treatment lasts for 6 weeks and does not include administration of either interferon or ribavirin, and said direct acting antiviral agents comprise (a) glecaprevir or a pharmaceutically acceptable salt thereof and (b) pibrentasvir or a pharmaceutically acceptable salt thereof.